Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ULK1 | O75385 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674949 | 0.84 | GAA (0.33) | GAAHTTRECQLMAPTCASP1 | |
| SCHEMBL27897072 | 0.81 | KMT2A (0.37) | HTTRECQLMAPTCASP1NQO2 | |
| SCHEMBL27955259 | 0.81 | CA2 (0.34) | GAAHTTRECQLCA2CA4 | |
| SCHEMBL16926925 | 0.79 | GAA (0.31) | GAAHTTRECQL | |
| SCHEMBL790816 | 0.79 | MAPT (0.36) | GAAHTTRECQLMAPTCASP1 | |
| SCHEMBL19783692 | 0.79 | ULK1 (0.37) | GAAHTTRECQLULK1AURKA | |
| SCHEMBL31342297 | 0.79 | ULK1 (0.37) | GAAHTTRECQLULK1AURKA | |
| SCHEMBL14853132 | 0.79 | PIK3CA (0.34) | HTTRECQLAURKA | |
| SCHEMBL676712 | 0.79 | DAO (0.33) | TSHR | |
| SCHEMBL22448808 | 0.77 | ALOX5 (0.35) | GAACA2CA4MAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-114853730-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117229202-B | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117229202-A | Preparation method of intermediate of BRD9 targeted degradation compound | 苏州美诺医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-3860980-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166062-A | 8-aminoisoquinoline compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3826722-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112601584-A | Isoquinoline compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020023560-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | GAA 2718/4885HTT 2968/4885RECQL 272/4885 |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | PHKG1, MAP4K5, HIPK1 | GAA 2586/4885HTT 3690/4885RECQL 370/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | GAA 2586/4885HTT 3690/4885RECQL 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.